The Directory of Pharma Companies and News


Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative speciality medicines to meet significant unmet patient needs. We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.


Shire News

2017-01-04Shire to present at the 35th Annual J.P. Morgan Healthcare Conference
2017-01-04Shire Announces Seventh Annual Scholarship for Individuals With ADHD
2016-12-27Shire announces FDA approval of ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated] for use in Children and...
2016-12-06Planning permission granted for new Shire manufacturing site in Ireland
2016-12-02Topline results of Phase 3 investigational study of VONVENDI™ [von Willebrand factor (Recombinant)] meets primary endpoi...
2016-12-02Shire reports on four decades of real-world safety experience with FEIBA® [Anti-Inhibitor Coagulant Complex]
2016-12-01Shire named "Pharma Company of the Year" by Scrip
2016-11-22Shire to Establish Rare Disease Innovation Hub in Cambridge, Mass.
2016-09-23Shire Closes Public Offering of Senior Notes
2016-09-19Shire Prices Public Offering of Senior Notes
2016-09-16District Court Issues Ruling in Hatch Waxman Case Regarding Shire’s LIALDA®
2016-09-14Shire announces U.S. FDA approval of CUVITRU™ [immune globulin subcutaneous (human), 20% solution] treatment for Primary...
2016-09-02U.S. Securities and Exchange Commission filings
2016-08-29Shire’s First Prescription Eye Drop, Xiidra™ (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.
2016-08-25Shire and Jennifer Aniston Want to Inspire People to Show Their Eyes Some Love and Help Raise Awareness of Chronic Dry E...
2016-08-19Elections for the interim dividend in respect of the six months to June 30, 2016
2016-08-08Half-yearly Report
2016-08-01Shire delivers strong Q2 2016 revenue growth; upgrades outlook
2016-07-29Shire’s SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for Adults who have Nona...
2016-07-29Shire Recommends ADS Holders Reject TRC Capital's “Mini-Tender Offer”
2016-07-25ONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas wh...
2016-07-21Shire launches pediatric indication for immunodeficiency treatment HyQvia in Europe
2016-07-20Shire to announce second quarter 2016 results
2016-07-20Shire Announces Award Recipients for Sixth Annual Scholarship for Individuals with ADHD
2016-07-19Shire reinforces commitment in Hematology with robust data presented at international congress of the World Federation o...
2016-07-11FDA Approves Shire’s Xiidra™ (lifitegrast ophthalmic solution) 5% – The Only Treatment Indicated for the Signs and Sympt...
2016-07-07Shire Receives Extension of Market Authorization in Europe for Revestive ? (Teduglutide) for the Treatment of Paediatric...
2016-06-30Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants
2016-06-29Shire Announces Positive Topline Results of SHP465 Efficacy and Safety Study in Adults with ADHD
2016-06-15Shire Launches 2016 Excellence in ADHD Patient Group Awards
2016-06-15Shire and Kamada announce FDA approval of expanded label for self-infusion of Glassia for the treatment of emphysema due...
2016-06-14Shire to License PF-00547659 from Pfizer, Adding to Established and Leading Gastrointestinal Portfolio
2016-06-13Shire Receives FDA Breakthrough Therapy Designation for SHP621 and SHP625, Investigational Products for Rare Gastrointes...
2016-06-10Shire announces completion of decentralized procedure in Europe for Immunoglobulin Treatment Cuvitru
2016-06-03Shire completes combination with Baxalta creating the global leader in rare diseases and highly specialized conditions
2016-05-27Result of Meeting - Shire shareholders vote to approve combination with Baxalta
2016-05-27Shire Receives Positive CHMP Opinion in Europe for Revestive® (Teduglutide) for Paediatric Patients with Short Bowe...
2016-05-15Shire’s Campaign to Support International Mucopolysaccharidosis (MPS) Awareness Day Takes Off
2016-05-11Shire to Present New Research at 2016 American Psychiatric Association Annual Meeting
2016-04-29Shire delivers strong Q1 2016 results with double-digit growth in revenue and Non GAAP earnings per ADS
2016-04-28Results of the 2016 Annual General Meeting
2016-04-27Shire to participate at the Deutsche Bank 41st Annual Health Care Conference
2016-04-18Publication of Circular, Notice of General Meeting and Prospectus and Directorate Change
2016-04-15Shire to announce first quarter 2016 results
2016-04-14Shire Submits NDA to FDA for New Formulation of Vyvanse® (lisdexamfetamine dimesylate) CII as Chewable Tablets
2016-04-11Income Access Share arrangements – dividend in respect of the six months to December 31, 2015
2016-04-06Shire Comments on Recent US Treasury Notice
2016-04-04Shire Announces Positive Results of SHP465 Safety and Efficacy Study in Children and Adolescents with ADHD
2016-03-29Shire Wins Patent Trial against Watson Concerning LIALDA®
2016-03-292015 Annual Report – DTR 6.3.5 Disclosure
2016-03-16Holding(s) in Company
2016-03-03Shire to participate at the Cowen 36th Annual Healthcare Conference
2016-03-03Developments to Income Access Share arrangements
2016-02-29Director/PDMR Shareholding - Amendment
2016-02-23Developments to Income Access Share arrangements – elections for the interim dividend in respect of the six months to De...
2016-02-16Elections for the interim dividend in respect of the six months to December 31, 2015 – developments to Income Access Sha...
2016-02-11Shire announces Full Year 2015 Results
2016-02-10Shire Partner, Shionogi, Submits New Drug Application in Japan for ADHD treatment for children
2016-02-09Shire Marks 30th Anniversary with Innovative Global Program to Benefit Children with Rare Diseases
2016-02-04U.S. FDA Acknowledges Receipt of Resubmission of Shire’s New Drug Application for Lifitegrast for Dry Eye Disease in Adu...
2016-01-28Shire to announce Full Year 2015 results
2016-01-28Shire PLC assigned investment grade credit ratings by Moody’s and S&P
2016-01-25Shire Resubmits New Drug Application for Lifitegrast to U.S. FDA
2016-01-22Shire Completes Acquisition of Dyax
2016-01-20Shire Moves Up 10 Positions on the Global 100 Sustainability Index
2016-01-11Shire to Combine with Baxalta, Creating the Global Leader in Rare Diseases
2015-12-15Shire to Present at 34th Annual J.P. Morgan Healthcare Conference
2015-12-09Shire Partners with CrowdMed to Offer US Employees an Innovative Digital Crowdsourcing Diagnostic Service
2015-12-04Directorate change
2015-11-24Shire to participate at the Piper Jaffray 27th Annual Healthcare Conference
2015-11-02Shire to Acquire Dyax Corp, expanding and extending industry-leading Hereditary Angioedema (HAE) portfolio
2015-10-27Shire's OPUS-3 Phase 3 Trial with Lifitegrast Meets Primary and Key Secondary Endpoints, Significantly Reducing Pati...
2015-10-23Shire announces third quarter earnings and reiterates full year guidance
2015-10-22Shire Announces 2015 Excellence in ADHD Patient Group Award Winners
2015-10-19Shire Provides Update on Next Steps for Lifitegrast in Light of FDA Complete Response Letter
2015-10-16Shire Receives FDA Complete Response Letter for Lifitegrast NDA and Plans to Respond with OPUS-3 Trial
2015-10-13Shire’s CINRYZE® (C1 esterase inhibitor [human]) Receives FDA Fast Track Designation for Investigation in the Treat...
2015-10-13Shire to Announce Third Quarter 2015 Results
2015-10-01Shire Announces Winners of Spotlight on Gaucher Film Contest to Mark International Gaucher Day
2015-10-01Shire Employees Embrace First Global Day of Service
2015-09-29Shire to participate at the Leerink Partners 4th Annual Rare Disease Roundtable
2015-09-24Appeals Court Affirms Shire’s Vyvanse® (lisdexamfetamine dimesylate) Patents Are Valid Until 2023
2015-09-21Shire Receives European Approval for INTUNIV® ? (guanfacine hydrochloride prolonged release tablets) as a Non-stimu...
2015-09-14Shire to Participate at Two Upcoming Investor Conferences
2015-09-01Shire Appoints Sara Mathew to Board of Directors
2015-08-25Shire to Attain Enhanced CINRYZE® Manufacturing Flexibility and Capacity
2015-08-25Shire to Attain Enhanced CINRYZE® Manufacturing Flexibility and Capacity
2015-08-24Elections for Interim Dividend
2015-08-10Shire Launches 2015 Excellence in ADHD Patient Group Awards
2015-08-04Shire proposed combination with Baxalta
2015-08-03Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset
2015-07-23Shire announces second quarter earnings and increases full year Non GAAP diluted EPS guidance to mid-to-high single digi...
2015-07-23Shire is recognized as a constituent of the FTSE4Good Index Series
2015-07-23Shire receives CHMP Positive Opinion in Europe for INTUNIV® (guanfacine hydrochloride extended release) as a non-st...
2015-07-23Shire receives CHMP Positive Opinion in Europe for INTUNIV®? (guanfacine hydrochloride extended release) as a non-s...
2015-07-23Shire receives CHMP Positive Opinion in Europe for INTUNIV®? (guanfacine hydrochloride extended release) as a non-stimul...
2015-07-22Vyvanse® (lisdexamfetamine dimesylate) Positive Top-Line Results in Maintenance of Efficacy Study in Adults with Mo...
2015-07-09Shire to announce second quarter 2015 results
2015-07-01Shire Launches Spotlight on Gaucher Film Contest and Calls for Video Entries Sharing Experiences of Living with Gaucher ...
2015-06-22Holding(s) in Company – Amendment
2015-06-15Shire names Bill Mordan General Counsel and Corporate Secretary; appoints Michele Galen Head of Communications and Publi...
2015-06-11Shire appoints Olivier Bohuon to its Board of Directors
2015-06-03Shire Receives European Approval to Use Resolor® (prucalopride) in Men for the Symptomatic Treatment of Chronic Con...
2015-06-01Shire to participate at the Jefferies 2015 Global Healthcare Conference
2015-05-26New Shire research to be presented at World Congress on ADHD highlights treatment portfolio, pipeline and caregiver expe...
2015-05-20Shire participates in Front End of Innovation (FEI) 2015 conference
2015-05-15Shire Named One of America’s Most Reputable Companies by Reputation Institute
2015-05-15Shire Recognizes HAE Day with Launch of Interactive Website Calling for Inspirational Wishes
2015-05-15Shire Named One of Americas Most Reputable Companies by Reputation Institute
2015-05-11Shire to Present New Research at American Psychiatric Association Annual Meeting
2015-05-06Shire to participate at the Deutsche Bank 40th Annual Healthcare Conference
2015-05-06Jeff Poulton appointed as Chief Financial Officer - Principle terms of remuneration
2015-05-04Shire and Foundation Fighting Blindness Announce New Research Agreement
2015-04-30Jeff Poulton Appointed Shire Chief Financial Officer and Joins Board of Directors
2015-04-30Shire delivers strong revenue growth and cash generation; 20% increase in Non GAAP earnings per ADS
2015-04-28Results of the 2015 Annual General Meeting
2015-04-21Shire to announce first quarter 2015 results
2015-04-09Shire Reports Topline Results from First of Three Placebo-Controlled Phase 2 Studies of SHP625 (LUM001) in Children with...
2015-04-09U.S. FDA Grants Priority Review to Lifitegrast NDA for the Treatment of Dry Eye Disease in Adults
2015-04-07Shire Announces Clear Regulatory Path Forward for SHP465, an Investigational Treatment for Adults with ADHD
2015-04-06Shire Comments on USPTO Petitions Related to LIALDA and GATTEX
2015-04-01Natpara® (parathyroid hormone) for Injection Now Available in the U.S.
2015-03-26Shire and Cincinnati Children’s Establish Rare Disease Research Collaboration
2015-03-262014 Annual Report - DTR 6.3.5 Disclosure
2015-03-23Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) 10 mg Now Available as a Titration Dose
2015-03-09Block Listing Application
2015-03-04Director Declaration
2015-03-03Director/PDMR Shareholding
2015-03-02Elections for Interim Dividend in Respect of the Six Months to December 31, 2014
2015-03-02Shire Submits Application to the U.S. FDA for Approval of Lifitegrast For Treatment of Dry Eye Disease in Adults
2015-03-02Total Voting Rights
2015-02-25Shire to Present at the Cowen 35th Annual Healthcare Conference
2015-02-24Shire Acquires Meritage Pharma
2015-02-23Shire calls for improved rare disease diagnosis on Rare Disease Day 2015
2015-02-21Shire Completes Acquisition of NPS Pharma
2015-02-13Director/PDMR Share Dealings
2015-02-12Shire delivers record revenues and Non GAAP earnings per ADS in 2014, and enters 2015 with strongest-ever pipeline
2015-02-04Shire to announce Full Year 2014 results
2015-02-03Director/PDMR Share Dealings
2015-02-03Tennis Star Monica Seles Partners with Shire to Raise Awareness of Binge Eating Disorder in Adults
2015-02-02Total Voting Rights
2015-01-30Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) Becomes First and Only Treatment Approved by the FDA for Adults wi...
2015-01-27U.S. Supreme Court Grants Shire Petition
2015-01-26Shire’s investigational SHP609, idursulfase-IT, receives FDA Fast Track designation for the treatment of neurocognitive ...
2015-01-23Shire Comments on Press Release from NPS Pharma Regarding FDA Approval of NATPARA® (parathyroid hormone)
2015-01-22Positive response from European Decentralised Procedure for Elvanse Adult® in adults with ADHD
2015-01-21Shire Added to Global 100 Sustainability Index
2015-01-11Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech
2015-01-08Director/PDMR Share Dealings
2015-01-06Shire to Present at 33rd Annual J.P. Morgan Healthcare Conference
2015-01-02Director/PDMR Share Dealings
2015-01-02Total Voting Rights
2014-12-23Director/PDMR Share Dealings
2014-12-10Shire R&D Day Profiles Innovative Pipeline Expected to Contribute $3 Billion in Product Sales by 2020
2014-12-01Shire to Highlight Pipeline Progress and Breadth of Innovative Portfolio in R&D Day
2014-12-01Total Voting Rights
2014-11-24Block Listing Six Monthly Return
2014-11-19Shire to Relocate Over 500 Jobs to Massachusetts
2014-11-14Block Listing Application
2014-11-11New Survey Reveals ADHD in Girls Is Misunderstood
2014-11-06Shire to participate at the Credit Suisse 2014 Global Healthcare Conference
2014-11-03Director/PDMR Share Dealings
2014-11-03Total Voting Rights
2014-10-31Notification of major interests in shares
2014-10-27Director/PDMR Share Dealings
2014-10-24Director/PDMR Share Dealings
2014-10-24Shire's clear and focused strategy delivers record quarterly revenues. Non GAAP diluted earnings per ADS up 60%
2014-10-21Shire to announce third quarter 2014 results
2014-10-20AbbVie terminates offer for Shire. Break fee of $1.635bn now payable. Independent Shire positioned for sustainable growt...
2014-10-20AbbVie terminates offer for Shire
2014-10-20Interim Chief Financial Officer James Bowling to Step Down
2014-10-16Statement re: AbbVie’s withdrawal of recommendation
2014-10-15Statement re: waiver of notice of AbbVie’s Board meeting
2014-10-15Statement re: AbbVie’s intention to reconsider recommendation
2014-10-09Shire Provides Regulatory Update on SHP 465, Investigational Compound for ADHD in Adults
2014-10-01FORM 8 (DD) - Shire plc
2014-10-01FORM 8 (DD) - Shire plc
2014-10-01FORM 8 (DD) - Shire plc
2014-10-01FORM 8 (DD) - Shire plc
2014-10-01FORM 8 (DD) - Shire plc
2014-10-01FORM 8 (DD) - Shire plc
2014-10-01FORM 8 (DD) - Shire plc
2014-10-01FORM 8 (DD) - Shire plc
2014-10-01Total Voting Rights
2014-09-30Director Share Dealings
2014-09-24Shire Reaches Final Agreement with U.S. Government
2014-09-15Shire Announces FDA Acceptance for Filing with Priority Review of Supplemental New Drug Application (sNDA) for Vyvanse® ...
2014-09-01Elections for Interim Dividend in Respect of the Six Months to June 30, 2014
2014-09-01Total Voting Rights
2014-08-21ViroPharma Incorporated - Consolidated Financial Statements
2014-08-13Updated Rule 2.10 Announcement
2014-08-11Updated Rule 2.10 Announcement
2014-08-07Updated Rule 2.10 Announcement
2014-08-05Updated Rule 2.10 Announcement
2014-08-01Half Yearly Report
2014-08-01Total Voting Rights
2014-08-01Updated Rule 2.10 Announcement
2014-07-30Updated Rule 2.10 Announcement
2014-07-29Director/PDMR Share Dealings
2014-07-28Updated Rule 2.10 Announcement
2014-07-24Updated Rule 2.10 Announcement
2014-07-23Shire Enters Strategic Licensing and Collaboration Agreement with ArmaGen
2014-07-23Updated Rule 2.10 Announcement
2014-07-21Updated Rule 2.10 Announcement
2014-07-18Recommended combination of Shire and AbbVie
2014-07-18Shire delivers record quarterly revenues and Non GAAP diluted earnings per ADS up 42%
2014-07-17Top-Line Results From Two Head-to-Head Studies Comparing Vyvanse® (lisdexamfetamine dimesylate), CII, With Concerta® (me...
2014-07-17Updated Rule 2.10 Announcement
2014-07-15Updated Rule 2.10 Announcement
2014-07-14Update re: AbbVie Proposal
2014-07-11Statement re: Media Speculation
2014-07-11Updated Rule 2.10 Announcement
2014-07-09Updated Rule 2.10 Announcement
2014-07-08Statement re: AbbVie Announcement
2014-07-07Updated Rule 2.10 Announcement
2014-07-03Form 8 (OPD) AbbVie Inc.
2014-07-03Form 8 (OPD) Shire plc
2014-07-03Updated Rule 2.10 Announcement
2014-07-01Total Voting Rights
2014-07-01FORM 8 (DD) - Shire plc
2014-07-01FORM 8 (DD) - Shire plc
2014-07-01FORM 8 (DD) - Shire plc
2014-07-01FORM 8 (DD) - Shire plc
2014-07-01FORM 8 (DD) - Shire plc
2014-07-01FORM 8 (DD) - Shire plc
2014-07-01FORM 8 (DD) - Shire plc
2014-07-01FORM 8 (DD) - Shire plc
2014-07-01Updated Rule 2.10 Announcement
2014-06-30Director/PDMR Share Dealings
2014-06-30Shire receives US$248 million cash refund from the Canadian revenue authorities, expects a further US$162 million in lat...
2014-06-27Updated Rule 2.10 Announcement
2014-06-26Updated Rule 2.10 Announcement
2014-06-25Shire Comments on AbbVie's Unchanged Proposal
2014-06-25Vyvanse Patents Found to Be Infringed and Valid by U.S. District Court
2014-06-23The Path to US$10 Billion in Product Sales by 2020
2014-06-23Shire to host investor call
2014-06-20Shire Update Call for Investors
2014-06-20Shire Confirms Rejection of AbbVie Proposal
2014-06-18Shire Launches Excellence in ADHD Patient Group Awards
2014-06-12Shire Agrees to FDA Request to Conduct Clinical Trials Investigating the Potential Use of Vyvanse® (lisdexamfetamine dim...
2014-06-10Shire to participate at the Goldman Sachs 35th Annual Global Healthcare Conference
2014-06-02Shire to present at the Jefferies 2014 Global Healthcare Conference
2014-06-02Total Voting Rights
2014-05-23Block Listing Six Monthly Return
2014-05-16Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults
2014-05-12Shire adds to rare disease portfolio with acquisition of Lumena Pharmaceuticals, bringing late stage compounds for rare ...
2014-05-02Shire to Present Scientific Data at American Psychiatric Association Annual Meeting
2014-05-01Shire delivers a strong start to 2014 and increases full year guidance
2014-05-01Total Voting Rights
2014-04-30Shire Announces Updates from Phase 3 Clinical Program for Lifitegrast in Adults with Dry Eye Disease
2014-04-29Results of the 2014 Annual General Meeting
2014-04-17First quarter 2014 results date notification - May 1, 2014
2014-04-15Pre-quarterly Results Communication
2014-04-01Director/PDMR Share Dealings
2014-04-01Total Voting Rights
2014-03-31Director/PDMR Share Dealings
2014-03-27Shire submits INTUNIV® (guanfacine extended release) Marketing Authorisation Application to EMA
2014-03-272013 Annual Report - DTR 6.3.5 Disclosure
2014-03-14Director Declaration
2014-03-14Shire Pharmaceuticals Initiates Voluntary Nationwide Recall Of One Batch, Packaged into Three Lots, of VPRIV® (velagluce...
2014-03-07Director/PDMR Shareholding
2014-03-06Director/PDMR Shareholding
2014-03-04Shire to present at the Cowen and Company 34th Annual Health Care Conference
2014-03-03Elections for Interim Dividend in Respect of the Six Months to December 31, 2013
2014-03-03Director/PDMR Shareholding
2014-03-03Total Voting Rights
2014-02-28Shire Recognizes Rare Disease Day 2014
2014-02-25ViroPharma announces results of tender offer for its 2.00% Convertible Senior Notes Due 2017
2014-02-21Director’s Share Dealings
2014-02-20Director's Share Dealings
2014-02-17Director's Share Dealings
2014-02-13Chief Financial Officer Graham Hetherington to step down
2014-02-13Shire delivers double digit product sales growth and 23% increase in Non GAAP earnings per ADS
2014-02-06Shire Reports Top-line Results from Two Phase 3 Studies for Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) as an ...
2014-02-04Historical income statements recast for DERMAGRAFT discontinued operations
2014-02-03Total Voting Rights
2014-01-30Full Year 2013 results date notification – February 13, 2014
2014-01-24ViroPharma announces tender offer for its 2.00% Convertible Senior Notes Due 2017
2014-01-24Shire successfully completes tender offer for ViroPharma
2014-01-23Susan Kilsby to succeed Matthew Emmens as Chairman of Shire
2014-01-17Cancellation of listing and admission to trading of Shire plc Convertible Bonds due 2014
2014-01-17Shire Executes Agreement to Divest DERMAGRAFT®
2014-01-15Shire waives OFT condition relating to the acquisition of ViroPharma Inc.
2014-01-14Guidance Update
2014-01-10Shire extends tender offer for ViroPharma
2014-01-02Total Voting Rights
2013-12-27Shire extends tender offer for ViroPharma
2013-12-23Director Share Dealings
2013-12-22VIDEO: Shire's CEO Flemming Omskov talks to the Financial Times
2013-12-18Block Listing Six Monthly Return
2013-12-16Notice of Redemption of U.S.$1,100,000,000 2.75 per cent. Convertible Bonds due 2014
2013-12-13Total Voting Rights
2013-12-12Shire Launches Online Educational Resource Center for US Patients with Ulcerative Colitis
2013-12-11Hart-Scott-Rodino Waiting Period Expires for Shire’s Acquisition of ViroPharma
2013-12-10Total Voting Rights
2013-12-05Shire Reports Top-Line Results on OPUS-2, a Phase 3 Study Investigating the Use of Lifitegrast (5.0% Ophthalmic Solution...
2013-12-05Total Voting Rights
2013-12-02Total Voting Rights
2013-12-02Shire Enters Into Agreement to Supply Adderall XR® Authorized Generic
2013-11-27BRAVE Awards Recipients Announced
2013-11-26Additional Listing
2013-11-26Optional Redemption Notice
2013-11-26Notice of Redemption of U.S.$1,100,000,000 2.75 per cent. Convertible Bonds due 2014
2013-11-26Block Listing Application
2013-11-25Block Listing Six Monthly Return
2013-11-22Notification of major interests in shares
2013-11-14Director Share Dealings
2013-11-14Shire Urges People with Diabetes to Check Their Feet for Wounds on World Diabetes Day
2013-11-14Notification of major interests in shares
2013-11-13Notification of major interests in shares
2013-11-11Termination of Share Buyback program
2013-11-11Shire to acquire ViroPharma in strategic move to strengthen rare disease portfolio; will augment already strong growth p...
2013-11-08Transaction in Own Shares
2013-11-07Shire Updates on Reorganisation Programme
2013-11-06Transaction in Own Shares
2013-11-05Positive Top-line Results Shown for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules (CII) in Adults with Binge Eating ...
2013-11-04Block Listing Application
2013-11-01Director Share Dealings
2013-11-01Total Voting Rights
2013-10-31Shire announces fourth annual scholarship program for individuals with ADHD
2013-10-30Transaction in Own Shares
2013-10-25Transaction in Own Shares
2013-10-24Strong third quarter and increased Non GAAP earnings expectations
2013-10-23Non Executive Director Appointment
2013-10-23Transaction in Own Shares – Correction
2013-10-23Transaction in Own Shares
2013-10-18Transaction in Own Shares
2013-10-16Transaction in Own Shares
2013-10-11Transaction in Own Shares
2013-10-10Third quarter 2013 results date notification - October 24, 2013
Brought to you by - Latest Jobs in Pharma
Brought to you by - Latest Jobs in Pharma.